After a quick trial revamp, FDA lifts its clinical hold on Concert’s hair-loss drug
Less than two months after Concert Pharmaceuticals $CNCE rattled investors with the news that the FDA had placed a clinical hold on its drug CTP-543 for alopecia areata, an autoimmune condition linked to complete or partial hair loss, regulators have now taken the agency’s foot off the brakes.
But the biotech says it is also amending the trial design to test two low doses of the drug — 4 mg and 8 mg twice daily — versus a placebo before they carefully consider upping the dose.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
